Biohaven Ltd. $BHVN Holdings Raised by Readystate Asset Management LP

Readystate Asset Management LP increased its position in shares of Biohaven Ltd. (NYSE:BHVN) by 14.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 377,119 shares of the company’s stock after purchasing an additional 46,587 shares during the quarter. Readystate Asset Management LP owned 0.36% of Biohaven worth $5,661,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in BHVN. PNC Financial Services Group Inc. lifted its position in shares of Biohaven by 113.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after buying an additional 1,268 shares during the last quarter. PFS Partners LLC acquired a new stake in Biohaven during the third quarter worth about $60,000. Elkhorn Partners Limited Partnership lifted its holdings in Biohaven by 26.1% in the second quarter. Elkhorn Partners Limited Partnership now owns 5,800 shares of the company’s stock worth $82,000 after acquiring an additional 1,200 shares during the last quarter. Virtus Investment Advisers LLC boosted its stake in Biohaven by 47.7% in the second quarter. Virtus Investment Advisers LLC now owns 6,032 shares of the company’s stock valued at $85,000 after acquiring an additional 1,949 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Biohaven by 198.6% during the second quarter. Tower Research Capital LLC TRC now owns 8,031 shares of the company’s stock valued at $113,000 after purchasing an additional 5,341 shares during the last quarter. Institutional investors own 88.78% of the company’s stock.

Biohaven Stock Up 1.0%

Biohaven stock opened at $11.47 on Wednesday. Biohaven Ltd. has a 52 week low of $7.48 and a 52 week high of $42.33. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -1.51 and a beta of 1.14. The company’s 50-day moving average price is $11.51 and its two-hundred day moving average price is $12.92. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 1.91.

Analyst Ratings Changes

Several analysts recently issued reports on BHVN shares. Robert W. Baird set a $42.00 price target on Biohaven in a report on Wednesday, November 5th. William Blair reaffirmed a “market perform” rating on shares of Biohaven in a research report on Friday, December 26th. Raymond James Financial reissued a “strong-buy” rating on shares of Biohaven in a report on Wednesday, November 5th. Royal Bank Of Canada lowered their price target on shares of Biohaven from $19.00 to $9.00 and set a “sector perform” rating for the company in a research report on Thursday, November 6th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Biohaven in a report on Wednesday, November 5th. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $25.40.

Biohaven Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.